Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one is an experimental small molecule compound with the molecular formula C18H17N5O2 and a molecular weight of approximately 335.36 g/mol. It has not been approved for clinical use in any country and is not currently indicated for any disease. The compound has been studied structurally as a ligand in protein crystallography experiments—specifically as a binder to tRNA guanine transglycosylase (TGT), suggesting it may act as an inhibitor or modulator of this enzyme. However, there are no reported clinical trials or therapeutic indications for this molecule to date[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-amino-4-[2-(4-methoxyphenyl)ethyl]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one.